Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

The Caribbean's IC24 fleet was the marquee one-design action at the breezy St. Thomas International Regatta. Calm, cool, and ...

Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.

"It's going to be really hard for the world to catch up." Automaker unveils jet-inspired SUV with 'super impressive' features ...

BHPian saurabh89 recently shared this with other enthusiasts:3 years ownership reviewCompleted 3 years with my Honda city VX ...

VX One’s competed in their Victorian State Champs over the weekend as part of the Royal Brighton Yacht Club’s 150th ...

The product enables broadcasters to optimize their media workflows "by leveraging the power of hardware and the flexibility ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

UK ISP LilaConnect, which following the VX FIBER merger is now part of Freedom Fibre‘s new Fibre-to-the-Premises (FTTP) ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...